Lyophilization Services Gain Ground Amid Growing Biologics Market
The need for lyophilization services is growing as a burgeoning pipeline of new biologics matures.
A growing pipeline of biologics that encompass therapeutic antibodies, proteins, and emerging therapies is driving the demand for more lyophilization. As a result, biopharmaceutical companies are increasingly outsourcing lyophilization operations to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). It is estimated that the market for lyophilization services for biopharmaceuticals will grow by 9.5% annually between 2017 and 2027, and that North America and Europe will continue to dominate the market over the next decade.
Read this article in BioPharm International’sOutsourcing Resources February 2020 eBook.
Article Details
BioPharm International
eBook: Outsourcing Resources, February 2020
February 2020
Pages: 16–19
Citation
When referring to this article, please cite it as F. Mirasol, “Lyophilization Services Gain Ground Amid Growing Biologics Market," BioPharm International Outsourcing ResourceseBook (February 2020).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
